Full Press Release Details
Di Caro V, Cho E, Lizama B, et al. Identification of Molecular Correlates with CT1812 Treatment-related decrease in NfL CSF Levels Connected to Sigma-2 Receptor . Poster presented at AD/PD 2025 ; Vienna, Austria
CGTX Positive Sentiment
Identification of Molecular Correlates with CT1812 Treatment-related decrease in NfL CSF Levels Connected to Sigma-2 Receptor
Key Takeaway: The poster presented at AD/PD 2025 discusses the identification of molecular correlates associated with CT1812 treatment. It highlights a decrease in NfL CSF levels, which is linked to the Sigma-2 receptor. This finding may provide valuable insights into the therapeutic effects of CT1812.
Price reaction · baseline $0.4208 (2025-03-31 close) · hit pre-market · 3 other CGTX headline(s) in the window, move may be shared
day 0 close
-6.8%
day 1
-1.9%
day 3 · peak
-15.8%
Market Sentiment Analysis
POSITIVE FACTORS
- Identification of molecular correlates suggests potential therapeutic insights.
- CT1812 treatment shows promise in reducing NfL CSF levels.
- Connection to Sigma-2 receptor may enhance understanding of treatment effects.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Frequently Asked Questions
What is the significance of the CT1812 treatment?
CT1812 treatment is linked to a decrease in NfL CSF levels, indicating potential therapeutic benefits.
What were the findings presented at AD/PD 2025?
The findings include molecular correlates associated with CT1812 treatment and its effects on NfL CSF levels.
How does the Sigma-2 receptor relate to CT1812?
The Sigma-2 receptor is connected to the treatment effects of CT1812, providing insights into its mechanism.